Good Laboratory Practice (GLP)
ProPharma ensures global GLP and lab compliance with QMS development, inspection readiness, remediation, and quality oversight.
GLP Consulting Services
ProPharma's Quality & Compliance team offers Sponsors, laboratories, and CROs a full range of global good laboratory practice and compliance support services for Clinical Study, Pharmacy, CMO, CDMO, CROs, and third-party testing labs. We assist in achieving and maintaining full compliance with GLP, GCLP, OECD, CAP, and CLIA regulations. Our consultants combine deep regulatory knowledge, operational experience, and a global perspective to ensure your non-clinical, clinical development, and bio/analytical programs meet international standards to support compliance aspects such as:
- GLP QMS development and implementation
- Inspection readiness
- Remediation
- Quality oversight

Nonclinical GLP Laboratory Compliance Services
We offer comprehensive Good Laboratory Practice support for facilities, sponsors, and testing labs conducting regulated nonclinical safety and toxicology studies.
Our GLP services include:
- GLP Facility & Study Conduct Audits
- Bioanalytical and Histopathology Compliance Assessments
- Test Article and Specimen Handling Reviews
- Toxicology Study Design and In-Life Phase Oversight (In-Vivo / In-Vitro)
- Data Integrity Audits (21 CFR Part 11, OECD, ALCOA+)
- Regulatory Inspection Readiness (FDA, EMA, MHRA, PMDA)
Enabling IND/CTA/NDA Laboratory & Testing Compliance
We support the transition from discovery through Investigational New Drug (IND) and Clinical Trial Application (CTA) to New Drug Application (NDA) testing with compliance audits, quality management system support, data integrity monitoring, and QA oversight services.
Our services include:
- GLP Oversight of IND/CTA-Supporting Studies
- CRO and Laboratory Qualification Audits
- Electronic Lab System Assessments (LIMS, ELN, CDS)
- Sponsor Oversight SOPs and GLP Quality Systems
- Regulatory Submission Readiness (IND, CTA)
GCLP, CAP & CLIA Compliance for Clinical Trial Laboratory
Ensure your clinical trial testing laboratories meet GCLP, CLIA, and CAP requirements to support compliant and inspection-ready operations.
GCLP Compliance Services
For central labs, specialty labs, and sponsor-oversight programs:
- GCLP Audits and Mock Inspections
- SOP Development for Sample Handling and Bioanalytical Testing
- Chain of Custody and Logistics Reviews
- Laboratory Vendor Qualification and Monitoring
CAP/CLIA Compliance Services (U.S. Labs)
For clinical labs performing testing under U.S. regulations:
- CLIA Certification Consulting and Gap Assessments
- CAP Accreditation Preparation and Inspection Readiness
- QMS Implementation and Lab Process Optimization
- Response Planning for CAP/CLIA Deficiencies
- Audit and Validation of Laboratory Information Systems (LIS)
Clinical and CMC Transition Support
We support clinical development teams as they interface with data from nonclinical and early CMC programs.
Services include:
- GLP-to-GCP Data Traceability Audits
- Oversight of Bioanalytical Labs Supporting Clinical Trials
- Companion Diagnostic and Biomarker Lab Compliance Reviews
- Technical Transfer
and Method Transfer Compliance Reviews - GCLP/CMC Consulting for Clinical Sample Analysis
Analytical Testing Compliance for Sponsors
We help commercial and manufacturing organizations manage GLP-related functions within GxP environments.
Services include:
- Non-GMP Laboratory Phase Appropriate Best Scientific Practices Compliance
- GLP Audit of R&D Labs within GMP Sites
- Analytical Method Transfer Compliance Support
- Stability and Shelf-Life Study Review
General Laboratory Compliance Services
Whether you're preparing for an inspection or establishing your first QA system, our global consultants can help.
- Global Regulatory Intelligence (FDA, EMA, MHRA, OECD, WHO)
- SOP Development & GLP/GCLP Policy Creation
- Staff Training (GLP, GCLP, CAP, CLIA, Data Integrity)
- CAPA Planning
and Remediation Project Management - Mock Inspections and Enforcement Readiness Support
- Quality System Development and Staff Augmentation
Partner with ProPharma for Good Laboratory Practice Services
Partner with us for expert laboratory compliance and quality solutions. Contact ProPharma today to learn how we can support your organization's laboratory Quality Assurance needs.
News & Insights
June 8, 2026
Modernizing Case Management for Global Compliance
Discover how E2B (R3) is modernizing pharmacovigilance case management, improving compliance, and streamlining adverse event reporting across global regulatory authorities.
June 4, 2026
Accelerating European Market Entry: The Strategic Advantage of Using FDA Approva...
Learn how the UK's IRP can help FDA-approved therapies achieve faster UK market access, accelerate launch sequencing, and support global regulatory strategy.
May 27, 2026
ProPharma Appoints Adrian Pencak as Chief Commercial Officer
ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
June 2, 2026
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...